Pfizer to develop new vaccines on its own using mRNA technology - WSJ

[March 23, 2021]    (Reuters) -Pfizer Inc plans to tap the mRNA technology to make new vaccines for other viruses following the success of its COVID-19 shot, which was developed jointly with German partner BioNTech SE, the Wall Street Journal reported on Tuesday.

Pfizer logo is reflected in a drop on a syringe needle in this illustration photo taken March 16, 2021. REUTERS/Dado Ruvic/Illustration

The drugmaker said it was ready to pursue mRNA on its own following its experience in the past year working on the COVID-19 vaccine, the WSJ reported, citing an interview with Pfizer Chief Executive Officer Albert Bourla.

It did not, however, disclose any details about the viruses it was targeting.

Pfizer and BioNTech did not immediately respond to Reuters requests for comment.

Pfizer/BioNTech and Moderna's COVID-19 vaccines, authorized for emergency use in the United States, use mRNA technology.

The success of the technology is prompting drug developers to consider its use in other areas of medicine beyond vaccines, attracting billions of dollars in investment.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Anil D'Silva)

[© 2021 Thomson Reuters. All rights reserved.]

Copyright 2021 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.